Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
| Status: | Withdrawn |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | June 2014 |
| End Date: | October 2016 |
The purpose of this study is to determine if dynamic hyperinflation seen in patients with
idiopathic pulmonary artery hypertension (iPAH) improves with albuterol therapy.
idiopathic pulmonary artery hypertension (iPAH) improves with albuterol therapy.
Only a few small studies have evaluated the relationship between iPAH, expiratory flow
limitation, and exercise dyspnea. While not all patients with iPAH demonstrate airway
involvement, those who demonstrate dynamic hyperinflation (DH), defined as a variable and
temporary increase in end-expiratory lung volume, report increased dyspnea with exertion on
maximal testing. There is a continued need for adjuvant therapy in iPAH, and bronchodilators
have the potential to ameliorate dyspnea during exercise, which could lead to improved
quality of life in this disabling condition. This study will investigate the presence of
airway involvement in this population as measured by dynamic hyperinflation, and if there is
any improvement in function with the use of inhaled albuterol.
limitation, and exercise dyspnea. While not all patients with iPAH demonstrate airway
involvement, those who demonstrate dynamic hyperinflation (DH), defined as a variable and
temporary increase in end-expiratory lung volume, report increased dyspnea with exertion on
maximal testing. There is a continued need for adjuvant therapy in iPAH, and bronchodilators
have the potential to ameliorate dyspnea during exercise, which could lead to improved
quality of life in this disabling condition. This study will investigate the presence of
airway involvement in this population as measured by dynamic hyperinflation, and if there is
any improvement in function with the use of inhaled albuterol.
Inclusion Criteria:
- 18 years of age or greater.
- Idiopathic Pulmonary Arterial Hypertension, or Familial Pulmonary Arterial
Hypertension.
- Forced expiratory flow 75% (FEF75%) of ≤ 65% of predicted.
Exclusion Criteria:
- Clinical instability or change in medication therapy in preceding 3 months.
- Allergy or intolerance to inhaled albuterol.
- Body mass index > 30
- Active tobacco use, or > 10 pack-year smoking history.
- Lung disease other than pulmonary hypertension
- Forced expiratory volume in 1 second (FEV1) ≤ 80% of predicted.
- Pregnancy
- Inability to perform pulmonary function testing.
- Inability to perform cardiopulmonary exercise testing.
- Supplemental oxygen requirement.
- Inability to read and understand English.
- Historical 6-minute walk distance <150 meters
We found this trial at
1
site
Click here to add this to my saved trials
